PTC Therapeutics Enters Material Definitive Agreement

TL;DR

PTC Therapeutics just signed a big deal, details TBD.

AI Summary

On November 27, 2024, PTC Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but indicates it is a significant event requiring immediate disclosure.

Why It Matters

This filing signals a significant development for PTC Therapeutics, potentially involving a new partnership, acquisition, or licensing deal that could impact its future growth and product pipeline.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and implications of the agreement, which could be positive or negative for the company.

Key Players & Entities

• PTC Therapeutics, Inc. (company) — Filer of the 8-K report
• November 27, 2024 (date) — Date of the earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo
• $1.0 billion — pany will receive an upfront payment of $1.0 billion on the Effective Date and up to $1.9 bi
• $1.9 billion — billion on the Effective Date and up to $1.9 billion in development, regulatory and sales mi

Filing Documents

• tmb-20241127x8k.htm (8-K) — 51KB
• tmb-20241127xex99d1.htm (EX-99.1) — 36KB
• tmb-20241127xex99d1002.jpg (GRAPHIC) — 5KB
• 0001070081-24-000029.txt ( ) — 228KB
• tmb-20241127.xsd (EX-101.SCH) — 4KB
• tmb-20241127_def.xml (EX-101.DEF) — 3KB
• tmb-20241127_lab.xml (EX-101.LAB) — 16KB
• tmb-20241127_pre.xml (EX-101.PRE) — 9KB
• tmb-20241127x8k_htm.xml (XML) — 5KB

01. Entry Into a Material Definitive Agreement

Item 1.01. Entry Into a Material Definitive Agreement. On November 27, 2024, PTC Therapeutics, Inc. (the "Company"), PTC Therapeutics HD, Inc. and Novartis Pharmaceuticals Corporation ("Novartis") entered into a License and Collaboration Agreement (the "Agreement"), relating to the Company's PTC518 Huntington's disease program which includes related molecules. Under the Agreement, the Company will receive an upfront payment of $1.0 billion on the Effective Date and up to $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales. Pursuant to the Agreement, the Company will continue to conduct the ongoing Phase 2A Clinical Trial and the ongoing OLE Clinical Trial pursuant to its existing development plan, with the goal of transitioning the ongoing OLE Clinical Trial to Novartis within 12 months after the Effective Date (as defined below). Novartis will be responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed products worldwide. The Agreement will be effective on the date (the "Effective Date") the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has occurred and other customary conditions are met. The parties anticipate that the Effective Date will be in the first quarter of 2025. The Agreement will commence on the Effective Date and, unless earlier terminated in accordance therewith, shall continue in force and effect until (a) with respect to the royalty territory, on a licensed product-by-licensed product and country-by-country basis, the royalty term end date for such licensed product in such country and (b) with respect to the profit-sharing territory, on a licensed product-by-licensed product basis, until the exploitation of such licensed product has completely terminated. Either party may terminat

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On December 2, 2024, the Company issued a press release in which it announced the signing of the Agreement. The Company will hold a conference call at 8:30 am EST on December 2, 2024 to discuss this news. Directions on how to access the conference call are included in the press release, which is attached to this Current Report on Form 8-K (this "Report") as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The information set forth in or incorporated by reference into this Item 7.01, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 2, 2024 issued by PTC Therapeutics, Inc. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL Cautionary Statement Concerning Forward Looking Statements This Report contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this Report, other than statements of historical fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects for the Company, including with respect to the Company's right to receive any upfront payment from Novartis; the Company's right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis; the continued development of PTC518 ; PTC expected use of proceeds from the transaction; future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions. The Company's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for the Company's products or product candidates that the Company commercializes or may commercialize in the future; the expected benefits and opportunities related to the licensing agreement may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments an

View Full Filing

View this 8-K filing on SEC EDGAR